According to Future Market Insights, the global Severe Asthma Treatment Market sales will expand at a 5.1% CAGR from 2023 to 2033, reaching US$ 36.18 billion by 2033. Severe Asthma Treatment has undergone a huge shift with the emergence of biologics and customised treatments, offering hope to millions of individuals worldwide who suffer from the disease.
Biologics, which are made from living organisms, have emerged as a promising development in the treatment of severe asthma by targeting specific immune system pathways that cause inflammation in the airways. In clinical trials, these medications shown remarkable efficacy and are increasingly being used to treat severe asthma patients who do not respond well to standard therapy.
Get a PDF Sample with Latest Market Insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16760
Some of the most commonly used biologics for severe asthma treatment are omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab. These medications have been found to improve lung function, reduce asthma exacerbations, and improve overall quality of life in severe asthma patients when administered subcutaneously or intravenously.
The global Severe Asthma Treatment market is predicted to develop in the future years as more people are diagnosed with severe asthma and more breakthrough medications become available.
Key Takeaways from the Market Study
- The market for Severe Asthma Treatment is expected to increase at a 5.1% CAGR between 2023 and 2033.
- In 2023, it is expected that the inhaled route of administration would account for 40% of the severe asthma therapy market.
- North America is expected to retain 45% of the market for severe asthma therapy in 2023.
- Europe’s market for Severe Asthma Treatment is expected to account for 39% of the total by 2023.
“Advancements in treatments along with innovation of treatment options is expected to favor the growth of the market in the upcoming years.” states an FMI analyst
Ask Us Your Questions About This Report@ https://www.futuremarketinsights.com/ask-question/rep-gb-16760
Competitive Landscape
Key players in the Severe Asthma Treatment market are Teva Pharmaceutical, AstraZeneca, GlaxoSmithKline, Novartis, Sanofi, Regeneron Pharmaceutical, 4D Pharma plc, AB Pharma, Morphosys, Roche, Avalo Therapeutics, Suzhou Connect Biopharmaceuticals, Pieris Pharma, Biosion
- GlaxoSmithKline’s discovery and marketing of a biologic drug called Nucala has been one of the company’s most significant breakthroughs in the treatment of severe asthma (mepolizumab). Nucala is an anti-IL-5 monoclonal antibody that is used to treat severe eosinophilic asthma, which is characterised by high eosinophil levels in the blood and airways.
- Novartis’ most major contribution to the treatment of severe asthma (omalizumab) has been the development and commercialization of a biologic medication called Xolair. Xolair is a monoclonal anti-IgE antibody that is used to treat severe allergic asthma caused by allergens such as pollen, dust mites, and animal dander.
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the global Severe Asthma Treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
For in-depth competitive analysis, Buy Now@ https://www.futuremarketinsights.com/checkout/16760
Key Segments Profiled in the Severe Asthma Treatment Industry Survey
Drug Class:
- Reslizumab
- Benralizumab
- Anti-inflammatory
Route of Administration:
- Oral
- Inhaled
- Intravenous
- Subcutaneous
Device Type:
- Dry powder inhalers
- Metered dose inhalers
- Soft mist inhalers
About Future Market Insights, Inc.
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs